CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Eribulin +1 moredrug
Likely dose
Eribulin 14mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03526679
NCT03526679Phase 2Completed
CompareCT.gov

A Single-arm Phase Ib/II Study of the Combination of Lenvatinib and Eribulin in Advanced Adipocytic Sarcoma and Leiomyosarcoma (LEADER Study)

National Taiwan University Hospital·interventional·Posted May 16, 2018·Updated Dec 5, 2025

In Brief

A Phase 2 clinical trial evaluating Eribulin and Lenvatinib for Leiomyosarcoma and 3 related conditions. Completed, enrolled 30 participants across 2 sites.

Detailed Summary

This study is designed to test the safety and efficacy of the combination of lenvatinib, a drug that can inhibit the growth of supplying vessels around the tumors, and eribulin, a chemotherapy drug that targets the cancer cell during mitosis, in inoperable or metastatic adipocytic sarcoma and leiomyosarcoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeiomyosarcoma, Liposarcoma, Soft Tissue Sarcoma Adult, Advanced Cancer
CountriesTaiwan
CollaboratorsTaipei Veterans General Hospital, Taiwan

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 16, 2018
Enrollment StartJul 12, 2018
Primary CompletionJun 30, 2021
Study CompletionOct 30, 2025
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 8.1 years ago

Interventions

Eribulindrug

lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days

Lenvatinibdrug

lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days